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Abstract: Myeloid cells are a unique subset of leukocytes with a diverse array of functions within
the central nervous system during health and disease. Advances in understanding of the unique
properties of these cells have inspired interest in their use as delivery vehicles for therapeutic
genes, proteins, and drugs, or as “assistants” in the clean-up of aggregated proteins and other
molecules when existing drainage systems are no longer adequate. The trafficking of myeloid
cells from the periphery to the central nervous system is subject to complex cellular and molecular
controls with several ‘checkpoints’ from the blood to their destination in the brain parenchyma.
As important components of the neurovascular unit, the functional state changes associated
with lineage heterogeneity of myeloid cells are increasingly recognized as important for disease
progression. In this review, we discuss some of the cellular elements associated with formation and
function of the neurovascular unit, and present an update on the impact of myeloid cells on central
nervous system (CNS) diseases in the laboratory and the clinic. We then discuss emerging strategies
for harnessing the potential of site-directed myeloid cell homing to the CNS, and identify promising
avenues for future research, with particular emphasis on the importance of untangling the functional
heterogeneity within existing myeloid subsets.
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1. Introduction
Diseases of the central nervous system (CNS) are some of the most devastating contributors to
disease burden worldwide, and are associated with significant costs to healthcare and productivity [1–3].
Despite intensive research, treatment of pathology within the brain remains challenging due to
its relative isolation from components of the circulatory system by the blood–brain barrier (BBB).
Drug development for CNS disorders has been particularly challenging, as virtually all large
molecules and the vast majority of small molecules identified in vitro cannot reach the parenchyma
in vivo [4]. Accumulating evidence indicates that, rather than being completely separated from
the peripheral immune system, the normal CNS undergoes tightly regulated surveillance by
a variety of bone-marrow-derived immune cells, likely through several influx/efflux pathways [5–7].
This population of cells also appears to be crucial for neuronal development and function [8].
Also, the influx of leukocytes from the periphery is a hallmark of a number of autoimmune and
neurodegenerative conditions, and despite sharing morphological characteristics of CNS-resident
microglia, peripheral myeloid cells appear to possess non-redundant functions [6]. Importantly, in
many cases the BBB is not simply “leaky”, as dyes and small proteins do not cross from the vasculature
into the brain parenchyma [9]. This indicates that, under certain circumstances, leukocytes may in
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fact be invited guests to the CNS—participants in a coordinated series of interactions with the brain’s
endothelial, glial, and epithelial barriers to contribute to brain homeostasis.
In many CNS diseases and in response to irradiation, the key cell type involved in trafficking to
the parenchyma is the myeloid cell, a subset of leukocytes central to the innate immune system [10,11].
Myeloid cells are typically released from bone marrow as one of several subsets of monocytes,
and following migration to target tissues may differentiate into macrophages or dendritic cells [12].
These cells possess a remarkable diversity of functions, which are dependent on their lineage, gene
expression, surface molecules, and interactions with the surrounding environment via messenger
molecules such as cytokines and chemokines secreted by other cells. Most notably, they are capable
of destroying and clearing pathogens and debris independently via phagocytosis and secretion of
proteolytic enzymes, and also of presenting antigens to the adaptive arm of the immune system [13].
This indicates that such cells could be primed for a function of interest via drug administration,
genetic modification, or culture with certain molecules. Although transplantation into the CNS can
be achieved directly via stereotactic injection, the damage induced by this process precludes it from
routine use. Taking advantage of existing mechanisms of selective leukocyte extravasation into the
brain parenchyma has emerged as a promising strategy for CNS cell and gene therapy, with tantalizing
evidence of success in both preclinical and clinical applications.
The purpose of this review is to highlight the peculiar anatomy of the CNS and the unique
mechanisms by which it allows myeloid cells to participate in site-directed homing, immune surveillance,
and initiation of neuroprotective or neurotoxic activity. Additionally, promising developments in the use
of myeloid-derived cells in the treatment of diseases of the CNS are discussed, and we outline some
key targets for future research.
2. Contribution of Myeloid Cells to Central Nervous System (CNS) Homeostasis
2.1. The Resident CNS Myeloid Cell, the Microglia
Despite initial controversy as to their origin, it is now established that microglia are derived from early
yolk sac erythromyeloid precursors and migrate to the brain during early embryogenesis [14–16], where
they remain exclusively throughout life without substantial contribution from bone marrow-derived cells,
unless recruited in response to distress signals from the CNS parenchyma and associated endothelial
and glial barriers [11,17,18]. In their ramified state, microglia are far from ‘resting’, their processes
continuously extend and retract to survey the surrounding parenchyma [19]. In their activated state,
microglia- and CNS-infiltrating monocyte-derived macrophages both adapt an amoeboid morphology and
share expression of many surface molecules including major histocompatibility class II (MCHII) complexes,
which has made identifying the source of such cells in histological sections a challenge [10]. Recent data
have established that mouse microglia possess a unique transcriptional and proteomic signature [20,21],
including the unique expression of purinergic receptor P2Y12 [20,22] and transmembrane protein
119 [23] on the cell surface, now enabling specific labelling with antibodies. Evidence also indicates
there are likely to be several heterogeneous subsets of microglia with region-specific functions, with a
recent report highlighting a unique subset of fractalkine receptor (CX3CR1)-positive microglia present
in the subventricular zone (SVZ), rostral migratory stream, and olfactory bulb that lacked ‘typical’
microglial markers Iba1, isolectin B4, and CD68, and appeared to be involved in the migration and
integration of adult SVZ-derived neural progenitors into the olfactory bulb [24]. Other researchers
have also used bone marrow chimeras and promoter-driven transgenic animals to label resident and
infiltrating cells separately, and have found that in many conditions, the two subsets of cells vary
considerably in their ability to phagocytose pathological deposits of protein, recruit other immune
cells via antigen presentation, and contribute to pathology via production of neurotoxic substances [6].
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2.2. Non-Microglial Myeloid Cells: Location and Transport in and out of the CNS
In the periphery, immune cells can traffic between lymph nodes and target organs via the blood
and lymphatic vessels [25]. However, endothelial cells of CNS blood vessels are connected by tight
junctions, which tightly control the passage of nutrients and cells across the vessel walls, and, with
the exception of the meninges [26,27], the brain does not appear to have conventional lymphatic
vessels, with entry and drainage of interstitial fluid (ISF) and cerebrospinal fluid (CSF) largely along
narrow bulk flow channels in basement membranes of parenchymal blood vessels that do not support
the passage of cells [28–31], specifically referred to as paravascular influx of CSF and intramural
perivascular ISF drainage by Engelhart and colleagues in [7]. Also, the interfaces between the brain
parenchyma, the vasculature, and the CSF-filled subarachnoid space are lined with a layer of astrocytic
endfeet, which under normal conditions form an additional barrier to the transport of immune cells
into the parenchyma [32].
In the healthy CNS, non-microglial myeloid cells are found mostly within the subdural meninges,
the choroid plexus, the CSF, and in the perivascular place between microvascular endothelial cells and
the glia limitans of CNS blood vessels [28,33] (Figure 1). A recent fate-mapping study has uncovered
that, contrary to previous belief, under normal conditions most macrophages in the perivascular
and meningeal spaces derive from early fractalkine receptor (CX3CR1)-positive cells that migrate
during embryogenesis and, like microglia, remain relatively stable once in their compartments [34].
The choroid plexus, by contrast, houses a population of shorter-lived cells that are gradually replaced
in part by blood-borne monocytes. At this stage the functional relevance of these different subsets of
macrophages is not known, but putative functions of non-parenchymal CNS myeloid cells as a whole
include immune surveillance, regulation of CNS-specific T lymphocyte activity, and phagocytosis of
molecules from the CNS parenchyma [5]. Interestingly, two recent studies using two-photon intravital
microscopy have identified a small subset of cells residing in the juxtavascular parenchyma expressing
either the classical dendritic cell marker CD11c or fractalkine receptor CX3CR1 with processes extended
through the glia limitans into the perivascular space [35], or even further into the vascular lumen [36].
These reports extend on early identifications of microglia-like cells embedded in the glia limitans
identified by electron microscopy [37]. Another proposed route for brain-to-peripheral communication
pathway is the presentation of antigens to peripheral lymph nodes by myeloid cells migrating out
of the CNS along with the CSF [7]. These routes include from the subarachnoid space through the
cribriform plate into the lymphatics of the nasal submucosa [7,38], and the newly discovered meningeal
lymphatic vessels, which are closely associated with venous sinuses in the dura mater and contain
populations of immune cells in the steady state [26,27]. The relative contribution of these processes
to presentation of antigen to peripheral lymph nodes has yet to be elucidated, but is likely to play
an important role in the development of inflammatory disorders such as multiple sclerosis.
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Figure 1. Putative routes for the extravasation and egress of myeloid cells from the brain parenchyma. 
Cells can traffic from blood to the subarachnoid space in the meninges (a), where they may traffic into 
the Virchow–Robin spaces at the surface of the brain. Secondly, cells can reach the brain parenchyma 
via small vessels such as capillaries (b) and post-capillary venules, where they must pass the tight 
junctions of the microvascular endothelium and breach the glia limitans. Thirdly, cells can reach the 
cerebrospinal fluid (CSF) through the choroid plexus (c). Cells carrying antigens towards lymph 
nodes have been proposed to follow at least two routes out of the brain compartment; into lymphatic 
vessels located in the meninges (d), and with CSF through the cribriform plate alongside olfactory 
nerves (e). Arrows represent the proposed direction of cell trafficking. 
3. Passing the Checkpoints to the Parenchyma: A Focus on the Neurovascular Unit 
During certain disease states and in response to radiation-induced disruption of homeostasis, 
circulating myeloid cells migrate into the brain parenchyma and surrounding spaces, where they 
may participate in phagocytosis and proteolytic digestion of macromolecules such as amyloid beta 
[39], or initiate the recruitment of effector cells such as T cells towards sites of pathology [40]. Their 
entrance to these compartments involves receptor-mediated chemotaxis and extravasation across the 
blood vessel endothelium, where they may (1) pass through the leptomeningeal vessels and epithelial 
cells of surrounding choroid plexus into the CSF-containing ventricles, which flow into the 
subarachnoid space; (2) enter the subarachnoid space directly via the leptomeningeal vessels; or (3) 
enter the perivascular space of arteries or post-capillary venules bordered by the glia limitans [41,42]. 
In the case of the latter, infiltrating cells participate in receptor-mediated chemotaxis towards 
astrocyte-released chemokines such as chemokine ligand 2 (CCL2), and release proteolytic enzymes 
to facilitate their passage through the basement membranes of the glia limitans [43,44]. The following 
section will discuss the unique anatomy of the perivascular niche and the sequential steps followed 
by leukocytes to pass the cellular and molecular checkpoints from the blood into the brain. 
3.1. Anatomy of the Perivascular Niche 
The perivascular niche is a major site of influx of leukocytes during the induction of 
experimental autoimmune encephalitis (EAE) [7,40], and is an important site of amyloid-beta 
deposition in Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA) [30,45], indicating 
this region is a key target for resolution of brain pathology. The perivascular niche is a multi-layered 
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3. Passing the Checkpoints to the Parenchyma: A Focus on the Neurovascular Unit
During certain disease states and in response to radiation-induced disruption of homeostasis,
circulating myeloid cells migrate into the brain parenchyma and surrounding spaces, where they may
participate in phagocytosis and proteolytic digestion of macromolecules such as amyloid beta [39], or
initiate the recruitment of effector cells such as T cells towards sites of pathology [40]. Their entrance
to these compartments involves receptor-mediated chemotaxis and extravasation across the blood
vessel endothelium, where they may (1) pass through the leptomeningeal vessels and epithelial cells of
surrounding choroid plexus into the CSF-containing ventricles, which flow into the subarachnoid space;
(2) enter the sub rachnoid space directly via the leptomeningeal vessels; or (3) enter the perivascular
space of arteries or post-capillary venules borde ed by the glia limitans [41,42]. In the c se of the latter,
infilt ating c ls participate receptor-mediated chemotaxis towards astrocyte- el ased chemokines
such s chemokine ligand 2 (CCL2), and r lease proteolytic enzymes to facilitate their passage through
the basement membranes of the glia limitans [43,44]. The following section will di cus the unique
anatomy of the perivascular niche and the sequential steps followed by leukocytes to pass the cellular
and molecular checkpoints from the blood into the brain.
3.1. Anatomy of the Perivascular Niche
The perivascular niche is a major site of influx of leukocytes during the induction of experimental
autoimmune encephalitis (EAE) [7,40], and is an important site of amyloid-beta deposition in
Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA) [30,45], indicating this region
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is a key target for resolution of brain pathology. The perivascular niche is a multi-layered structure
composed of numerous interdependent cell types, which varies according to vessel type and location [7].
The post-capillary venules are the main site of leukocyte extravasation into the inflamed CNS and are
the primary site of “inflammatory cuffs” observed in models of EAE [40] (Figure 2). Nearby capillaries,
by contrast, do not have a “perivascular space” as the basement membranes of endothelial and glial
barriers are fused [7].
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Figure 2. Simplified schematic drawing of the anatomy and function of the perivascular niche.  
The blood–brain barrier consists of a layer of microvascular endothelial cells connected by selective 
tight-junctions that prevent the passage of most large molecules and cells. These junctions rapidly 
remodel to allow passage of leukocytes such as monocytes through to the glial and endothelial 
basement membranes. An important distinguishing feature between capillaries and post-capillary 
venules is the separation of glial and endothelial basement membranes in the latter (right), forming 
the perivascular space. Also embedded in the endothelial basement membrane are pericytes, a 
population of mesenchymal cells responsible for maintaining endothelial cell formation and function, 
and polarising astrocyte endfeet. Perivascular macrophages (labelled, right) may derive from 
embryonic precursors, or may arise from infiltrating monocytes that have passed through the post-
capillary endothelium. To reach the CNS parenchyma, cells must pass through the glia limitans, 
consisting of astrocyte endfeet attached to a basement membrane (arrows). This is achieved in part 
by coordinated chemotaxis with chemokines such as chemokine ligand 2 (CCL2; right arrow), and 
enzymatic digestion of intact basement membrane by matrix metalloproteinases (MMPs; left arrow). 
Also pictured are rare fractalkine receptor (CX3CR1)-positive parenchymal cells that appear to extend 
processes through the glia limitans, possibly to sample antigen from the perivascular niche. 
Enclosing the lumen of the post-capillary venule is a layer of specialised microvascular 
endothelial cells attached to a basement membrane connected by tight junctions intermingled with 
adherens junctions, which serve to regulate paracellular diffusion of ions and maintain cell–cell 
contacts, respectively [46]. The distinct morphology of the endothelial cells and associated zipper-
like junctions serve to tightly regulate the movement of nutrients and cells by forming an extremely 
selective physicochemical barrier [46,47]. The tight junctions themselves are composed of a network 
of transmembrane proteins including occludin, claudins, and junctional adhesion molecules [47]. 
These proteins are organized and linked to the cortical actin cytoskeleton by intracellular scaffolding 
proteins such as zonula occludens-1. For a review of tight and adherens junction components and 
their roles in maintenance of the BBB, see [46]. Embedded in the endothelial basement membrane are 
pericytes, thought to be derived from neural crest cells in the neuroectoderm, and mesenchymal stem 
cells in the mesoderm [48]. Pericytes are identified based on the expression of a number of molecules 
including platelet-derived growth factor receptor-β (PDGFR-β) [49], regulator of g-protein signalling 
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perivascular space. Also embedded in the endothelial basement me brane are pericytes, a population
of mesenchymal cells responsible for maintaining endothelial cell formation and function, and
polarising astrocyte endfeet. Perivascular macrophages (labelled, right) may derive from embryonic
precursors, or may arise from infiltrating monocytes that have passed through the post-capillary
endothelium. To reach the CNS parenchyma, cells must pass through the glia limitans, consisting of
astrocyte endfeet attached to a basement membrane (arrows). This is achieved in part by coordinated
chemotaxis with chemokines such as chemokine ligand 2 (CCL2; right arrow), and enzymatic digestion
of intact basement membrane by matrix metalloproteinases (MMPs; left arrow). Also pictured are rare
fractalkine receptor (CX3CR1)-positive parenchymal cells that appear to extend processes through the
glia limitans, possibly to sample antigen from the perivascular niche.
Enclosing the lumen of the post-capillary venule is a layer of specialised microvascular en othelial
cells attached to a basement membrane connected by tight j nctions intermingled with adherens
junctions, which serve to regulate paracellular diffusion of i ns and maintain cell–cell contacts,
respectively [46]. The dis inct morphology of the e dothelial cells and associated zipper-like
junctions serve to tightly regulate the mov men of nutrients and cells by forming an extremely
selective physicochemical barrier [46,47]. The tight j nctions themselves are composed of a network
of transmembrane proteins including occludin, claudins, and junctional adhesion molecules [47].
These proteins are organized and linked to the cortical actin cytoskeleton by intracellular scaffolding
proteins such as zonula occludens-1. For a review of tight and adherens junction components and
their roles in maintenance of the BBB, see [46]. Embedded in the endothelial basement membrane
are pericytes, thought to be derived from neural crest cells in the neuroectoderm, and mesenchymal
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stem cells in the mesoderm [48]. Pericytes are identified based on the expression of a number of
molecules including platelet-derived growth factor receptor-β (PDGFR-β) [49], regulator of g-protein
signalling 5 (RGS5) [50], and Aminopeptidase N (CD13) [51,52]. More reliably, pericytes can be
identified by their ultrastructural localization to the endothelial basement membrane in semi-thin
electron microscopy sections [53]. Although a number of studies have suggested that cells expressing
typical pericyte markers can migrate and differentiate into antigen-presenting cells in response
to ischemia or brain injury [54–57], there is still the possibility that experimental conditions as
such may induce the expression of the aforementioned ‘pericyte’ markers on myeloid cells [53].
Thus uncertainty remains over their lineage and differentiation capacity [55,58]. Of the many roles
ascribed to pericytes, there is strong evidence for a crucial role in the formation and function of
the BBB, participating in structural support of the mirovasculature, vasodynamic control, basement
membrane synthesis and repair, organization of endothelial cells, and the polarization of astrocyte
endfeet associated with the glia limitans [48,59,60]. Inside the perivascular space are a population of
fractalkine receptor-positive perivascular macrophages derived from early embryonic progenitors [34].
Under certain circumstances, particularly following irradiation or injury, these cells may also be
replaced by blood-borne progenitors [61–65]. Enveloping the perivascular space is the glia limitans,
a barrier formed by astrocyte endfeet and surrounding basement membrane. This barrier is the final
checkpoint for infiltrating immune cells to enter the brain parenchyma, and is a crucial regulator of
inflammatory processes and dysfunction of nearby neural tissue. For a review of molecular mediators
of astrocyte barrier function, see [66].
3.2. Initial Attraction: Monocyte–Endothelium Interactions
The migration of peripheral immune cells through the cerebral microvasculature follows the same
general course as in the periphery, starting with selectin and adhesion molecule-mediated tethering
and rolling of leukocytes to the endothelium, where they are activated, encounter integrins and
immobilized chemokine ligands, and, if recognized by their cognate receptors, will tightly adhere to
the endothelium and extend processes through the intercellular junctions to initiate diapedesis [39,67].
Although this remains to be confirmed in vivo, evidence from in vitro experiments indicates that
leukocytes may extravasate across the BBB endothelium in a paracellular (between cells) or transcellular
(through cells) fashion, with paracellular transport more common for monocytes and T cells, and
an apparent preference for tri-cellular junctions over the bi-cellular route [68,69]. By contrast,
neutrophils appear to favour the transcellular route through simulated blood-brain and blood-CSF
barriers [70,71]. Diapedesis, the passage of cells through an intact endothelial barrier, is associated
with rapid remodelling of tight junctions, such that as the leukocyte travels through the junction, the
gaps are rapidly replaced with membrane from the endothelial lateral border recycling compartment,
and the leukocyte itself forms transient connections with unligated cell adhesion molecules such as
PECAM1-1 and CD99 [68]. This serves to preserve BBB integrity and prevents uncontrolled influx
of solutes, proteins and other cells from the periphery during the process of extravasation. Thus the
leukocyte has passed the first ‘checkpoint’ through to the perivascular space without significantly
disrupting homeostasis.
3.3. Gatekeepers: Astrocytes and the Glia Limitans
Once inside the perivascular space, infiltrating immune cells may either remain within the
perivascular space, or may go on to breach the glia limitans. This is particularly pertinent in the case of
EAE, where activated T lymphocytes and monocyte-derived macrophages are known to breach the glia
limitans of the spinal cord through proteolytic cleavage of dystroglycan, laminin, extracellular matrix,
and other membrane proteins by matrix metalloproteinases (MMP-) 2, 7, and 9 [44]. Astrocytes also
release MMP-7, though to a lesser extent than myeloid cells [72]. Nonetheless, this may indicate that
the glia limitans itself is “inviting” the entry of immune cells from the perivascular space.
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3.4. Spotlight on Coordinated Chemotaxis: The CCL2/CCR2 Pathway
This concept of “invited” migration to the brain parenchyma during demyelination is even better
demonstrated with new insights gained regarding chemokine ligand 2 (CCL2), a crucial chemokine
for egress of monocytes from bone marrow, and their transport through both endothelial and glial
checkpoints to the brain parenchyma. Although many chemokines are expressed in the neurovascular
unit in response to pathological insults, CCL2 has received considerable attention as the ligand and
its receptor are essential for migration of the largest populations of leukocytes across the BBB in
many mouse models of injury and disease [43,73–78], and expression of CCL2 in response to brain
pathology is associated with production of many associated metalloproteinases and cytokines such
as MMP-10, MMP-12, IL-1, and TNF-α [78]. Many cells in the neurovascular unit can release CCL2
in response to insult or injury. These include neurons [79,80], astrocytes [43,73], microglia [73,81],
and microvascular endothelial cells [43]. The coordinated expression of chemokines from these
cells guides the extravasation of leukocytes from the vasculature, and towards the site of action.
For example, injured neurons in the superficial cervical ganglia express Ccl2 mRNA, but the ligand
itself is found localized to nearby microvascular endothelial cells, in which the mRNA expression of
Ccl2 is undetectable [79]. This appears to indicate that CCL2 has been released by the neurons and
has travelled through the extracellular space to the endothelial cells, where they bind to receptors and
are stabilized for presentation to infiltrating leukocytes. Another elegant study illustrates the relative
contribution of CCL2 release from astrocytes and endothelial cells in the recruitment of leukocytes
in EAE, by comparing astrocyte and endothelial-specific Ccl2-knockout mice [43]. When astrocyte
CCL2 is absent, infiltrating cells become trapped in the perivascular space, reducing the severity of the
pathology but maintaining the same time of onset. Conversely, if endothelial cell CCL2 is absent, the
pathology is delayed but similar in severity, with an apparent stalling of leukocytes in the vascular
lumen. In this case it is possible that the smaller chemokine gradients induced by the comparatively
distant release of CCL2 by astrocytes (and possibly other cells) was able to preserve leukocyte influx
to the parenchyma, albeit less efficiently. In summary, both major checkpoints of the neurovascular
unit appear to participate in the coordinated influx of immune cells from the periphery. Whether this
is a beneficial or detrimental response depends on the specific pathology, thus, chemokine-mediated
leukocyte influx remains a complex, yet promising target for therapeutic intervention.
4. Myeloid Cells: The White Knights of CNS Therapy?
The field of neuro-immunology has undergone a major shift in recent decades, sparked by the
recognition that infiltrating leukocytes and resident microglia can have both harmful and trophic
effects on diseased neural tissue. Immunotherapies are gaining traction as promising strategies for
treating a wide variety of diseases, with many clinical trials underway. However, therapeutic strategies
are yet to mature, likely because the true complexity of immune dysfunction within the CNS during
disease is not fully understood. In this section we will discuss the progress of research targeting the
transplantation of the myeloid family of cells for the resolution of a selection of diseases affecting
the CNS.
4.1. Genetic Deficiencies: Lysosomal/Peroxisomal Storage Diseases
Lysosomal storage diseases (LSDs) and peroxisomal storage diseases (PSDs) are rare, typically
fatal, multisystem childhood disorders usually resulting from a genetic deficiency of one or more
lysosomal/peroxisomal enzymes [82–84]. A major component of many LSDs/PSDs is progressive
neurodegeneration associated with accumulation of macromolecular substrates and associated
neuroimmune activity [85]. Bone marrow transplantation has been used for decades as a treatment
for MLD/LSDs; however, outcomes remain suboptimal, with incomplete resolution of symptoms,
graft-versus-host disease, and death still commonly reported [86]. In animal models, it is the F4/80+
myeloid cells that migrate into the brain parenchyma and phagocytose aberrant deposits of lipid
Int. J. Mol. Sci. 2016, 17, 2030 8 of 27
and other substrates following bone marrow transplantation, indicating that they are likely to be
the driver of therapeutic action [83,87–90]. Evidence from these experiments indicates it may be
possible to enhance treatment to prevent the impairments in motor conduction associated with LSDs
by transplanting gene-modified hematopoietic stem cells (HSCs) over-expressing the missing gene.
Other experiments have shown that this effect is enhanced when gene expression is tied to the CD11b
(myeloid-specific) promoter [91], in this case correcting both proteoglycan build-up and open-field
mouse behaviour.
Furthermore, the first clinical trial of autologous HSC transplantation with lentivirally transduced,
“supertherapeutic” ARSA gene expression in pre-symptomatic children with arylsulfatase A (ARSA)
deficiency (the cause of metachromatic leukodystrophy) was recently completed, and appears to have
been successful at preventing the demyelination associated with sulfatide accumulation for at least two
years post-therapy [92,93]. This promising data indicates myeloid cells are likely to be a key target for
gene therapy; however, longer term follow-up and larger studies will be needed to determine whether
the strategy successfully prevents the progression of disease. Also of interest would be whether this
strategy would be capable of arresting disease progression in patients already affected by the disease.
4.2. Neurodegenerative Diseases
Many neurodegenerative diseases are characterized by the aggregation of proteins and peptide
fragments within the brain, and the impaired clearance of these products is hypothesized to
underlie the pathogenesis of these diseases [53], although their role as initiators of disease remains
controversial [94–96]. Several pharmaceutical companies are progressing through clinical trials
utilizing targeted immunotherapy against aggregated protein products, either through vaccination
or antibody administration, with limited evidence of success. Initial data suggests these therapies
are unlikely to be a ‘magic bullet’ for neurodegeneration, as dramatic clinical improvement has yet
to be shown in phase III trials, and side effects have been relatively common [97,98]. In this section
we discuss the rationale and preclinical evidence behind targeted myeloid-based cell therapy for
a selection of neurodegenerative disorders, which may have the potential to enhance the clearance of
protein and peptide fragments from the CNS.
4.2.1. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia worldwide [99]. The hallmarks
of AD are progressive loss of neurons and synapses, associated with the presence of amyloid beta
(Aβ) plaques throughout the brain parenchyma and around blood vessels, and tau neurofibrillary
tangles [100]. In common with other brain pathologies, models of AD are associated with the presence
dystrophic microglia with characteristics of an activated state, such as an amoeboid morphology and
expression of MHC antigens, but with unique hallmarks of dysfunction including ultrastructural
signs of oxidative stress [101,102]. With the suggestion that dystrophic microglia accumulate over the
course of ageing and in many cases of neurodegenerative disease, microglial age-related senescence
was proposed as a key contributor to neurodegeneration. Microglial dysfunction appears to precede
alterations in processing and subsequent aggregation of Aβ, and has even been suggested to underlie
the disease itself [102–104]. In line with this theory, activation of complement cascade and aberrant
pruning of synapses by dysfunctional microglia are early events preceding the appearance of overt
pathology in some animal models of familial AD [105], and apparently occurs independently of
neuronal protein aggregation [106]. Several animal models of familial AD have nonetheless shown
that infiltrating monocyte-derived macrophages may be intimately involved in restricting disease
progression, possibly via the phagocytic clearance of Aβ [107–109]. Despite the controversy, clearance
of aggregated proteins remains a promising strategy for disease modification.
It has become evident that resident microglia and blood-derived macrophages behave differently in
the presence of Aβ [45]. Although microglia appear to internalize as much Aβ as peripheral macrophages
in vitro, subsequent lysosomal fragmentation is slow, incomplete, and easily overwhelmed by the
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presence of large amounts of protein [110]. Thus it is possible that infiltration of peripheral myeloid
cells is a protective response to amyloid loading. Interestingly, common genetic risk factors indicate that
impaired clearance of Aβ by macrophages may be a central part of disease pathogenesis. For example,
rare mutations in the triggering receptor expressed on macrophages-2 (TREM2) gene are associated with
an increased risk of developing neurodegenerative diseases including AD, and many mouse models
of familial Alzheimer’s display alterations in Trem2 expression [111,112]. Although animal models
report seemingly conflicting effects of eliminating or overexpressing Trem2 [113,114], and the relative
contribution of peripheral and CNS-resident cells is yet to be investigated, most studies agree that
the receptor (and by extension, myeloid cells) plays an important role in the response to deposition
of Aβ in AD, likely though effects on cell surface transport and phagocytosis [115,116]. The most
extensively recognized gene locus for AD risk is the APOE gene, with the APOE4 allele considered
risk-inducing, and APOE2 generally considered protective [117]. Macrophages are known producers of
apolipoprotein, and in vitro challenge of macrophages from AD transgenic mice expressing the three
major isoforms of APOE indicates that the APOE2 allele may confer an enhanced ability to phagocytose
Aβ on myeloid cells associated with increased expression of MMP-9 [118]. Additionally, transplantation
of APOE3, but not APOE4 expressing bone marrow improves pathology and behavioural changes in
double-transgenic AD mice in vivo [119]. Another strategy used in vivo was to disrupt transforming
growth factor-beta (TGF-β)-mediated transcription regulation driven by the myeloid-specific CD11c
promoter, which resulted in major attenuation of plaque formation (~90%) and improvement of
behavioural deficits in Tg2756 AD mice [108]. This was associated with increased infiltration of
macrophages around cerebral vessels and amyloid plaques in vivo, and enhanced phagocytosis
of Aβ by macrophages in vitro. Overall it appears that enhancing the Aβ clearance capacity of
macrophages by increasing lipid binding or proteolytic enzymes, or perhaps replacing senescent
microglia with enhanced cells to avoid unwanted bystander damage, might become a strategy for CNS
tissue regeneration.
Although current therapeutics approved for use in mild to moderate AD purportedly target
neurons directly, several lines of evidence indicate the myeloid lineage of cells may be additional
targets of these drugs. For example, acetylcholinesterase inhibitors have been used to enhance
cholinergic neurotransmission, and have been modestly successful at delaying cognitive decline [120].
Both blood-borne macrophages and resident microglia possess alpha 7 nicotinic acetylcholinergic
receptors, and their activation on microglial cells prevents Aβ-induced oxidative stress and facilitates
clearance of Aβ in vitro [121,122]. Thus it is tempting to speculate that the immunomodulatory
properties of these drugs may be contributing to their modest success. At present, a popular strategy
for eliminating Aβ in clinical trials is targeted immunization involving either an active vaccine against
specific Aβ fragments, or intravenous antibody infusion. The first vaccination trials with AN1792 were
discontinued due to the induction of meningoencephalitis associated with T-cell infiltration in several
patients [123], and treatment only elicited a sufficient antibody response in ~50% of patients [124].
Additionally, cerebral amyloid angiopathy persisted despite clearance of cortical plaques in more than
one case [125,126]. Similar rates of response have been observed in trials of a newer vaccine designed
to avoid the T-cell specific response observed in the AN1792 trial [127]. Given the limited response
rates to active vaccination (potentially due to age-related immune senescence), direct administration
of antibodies has been tested, but none of the phase III trials so far have demonstrated significant
improvements in symptoms or slowing of cognitive decline [97,98]. Interestingly, both animal models
and clinical trials have also demonstrated that CAA can persist after monoclonal antibody-mediated
parenchymal clearance of Aβ [128,129]. Although this is likely to depend on the specific target peptide
fragments, it does indicate that stimulating an endogenous immune response may not be sufficient to
arrest the progression of vascular Aβ deposition once it has already progressed, and perhaps that the
neurovascular unit may be a particularly important target for therapy in the future.
Although no transplantation trials appear to be in progress, one phase II trial is currently
underway investigating use of Granulocyte-Macrophage Colony-Stimulating Factor (Sargramostim;
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GM-CSF) for the mobilization of hematopoietic progenitors in patients with AD (NCT01409915).
Animal trials have indicated that improvements in amyloid load and cognitive function following this
treatment is associated with increased density of Iba-1 positive cells around plaques [130]. Although the
authors did not distinguish resident microglia from infiltrating myeloid cells, which also express Iba1,
it is possible that increased influx or priming of peripheral myeloid cells is driving this response.
Indeed, in vitro evidence suggests GM-CSF treatment of monocytes enhances their capacity to traffic
across endothelial barriers resembling the BBB, and promotes the release of reactive oxygen species
and interleukin-6 [131].
In summary, although the precise roles of specific myeloid subsets in the promotion or response
to neurodegeneration are yet to be fully untangled, accumulating evidence indicates that myeloid
cells from both within and outside the CNS have important roles to play in the modulation of
neurodegenerative processes. Thus, the myeloid lineage remains a key target for therapeutic strategies,
whether used to replace or support senescent microglia, or to facilitate clearance of aggregated proteins.
4.2.2. Amyotrophic Lateral Sclerosis (ALS)
ALS is a neurodegenerative disease characterized by the progressive loss of motor neurons in the
cerebral cortex, brain and spinal cord, resulting in paralysis and eventual death [132,133]. Many gene
mutations have been identified in familial cases, which has enabled the generation of transgenic
models to investigate pathogenesis and treatment options [134]. Evidence from superoxide dismutase-1
(SOD1) mutant mice suggests that non-neuronal cells contribute substantially to the neurodegenerative
process, and that myeloid cells in particular play an important role [135,136]. Although there appears
to be some disagreement over the role of monocyte infiltration in ALS progression, it appears the
phenotype of immune cells interacting with motor neurons changes throughout the course of disease,
indicating they could be a useful target for therapy [132,137]. Initial evidence for this line of enquiry
has come from a recent study, which has identified major alterations in composition and function of
peripheral monocytes in the blood of 10 ALS patients compared to controls [138]. Researchers found
blood from patients displayed an increase of classical, “inflammatory” CD14++CD16− monocytes
relative to non-classical CD14+CD16++ cells. In vitro, the CD16−monocytes from these patients were
significantly less efficient at phagocytosis of yeast-derived particles, and more inclined to adhere
to collagen-coated chamber walls under shear stress. Post-mortem investigations also indicated
an increase in migration of monocyte derived cells into the spinal cord of ALS patients. This raises the
possibility that in ALS, neurodegeneration is accompanied by an inefficient innate immune response,
which could be modulated by selective targeting of myeloid cells.
Clinical success for ALS has been limited. The drug most commonly used to address ALS, Riluzole,
appears to prolong patient survival by several months on average, with only small improvements
in motor function [139]. Riluzole is purported to reduce excitotoxicity associated with ALS via
the inhibition of neuronal glutamate release, in part through its actions on voltage-dependent
sodium channels [140]. Interestingly, a recent study has demonstrated that in vitro, Riluzole is
capable of modulating responses of rat microglia to inflammatory stimuli, possibly via activation
of two calcium-activated potassium channels, SK3 (KCa2.3) and SK4 (KCa3.1) [141]. Specifically,
administration of the drug attenuated “pro-inflammatory” cytokine mRNA expression in response
to lipopolysaccharide challenge, and enhanced expression of brain-derived neurotrophic factor (BDNF)
mRNA following stimulation with interleukin-4. Although further study is required to identify
the sites of action and therapeutic relevance of this effect, this study has highlighted a previously
under-recognized molecular pathway for neuroprotection.
Although therapeutic strategies targeting the myeloid lineage are yet to gain significant attention
in the clinic, several lines of evidence suggest it may gain traction in the future. For example,
SOD1 mutant mice transplanted with bone marrow stimulated by granulocyte colony stimulating
factor (G-CSF) were partially protected from motor neuron loss in the ventral horn of the spinal
cord [142]. This was accompanied by an influx of myeloid cells with a “microglial” phenotype, and
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increased expression of neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF),
brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and angiogenin.
Similar results were obtained in double-transgenic, immune cell-deficient mSOD1G93A/PU.1−/− mice,
in which transplantation with wild-type bone marrow was associated with a slowing of disease
progression compared to controls transplanted with marrow from mSOD1G93A mice [136]. Also,
a phase 1 trial using NP001 (sodium chlorite) to downregulate inflammatory pathways in myeloid cells
was conducted recently based on promising preclinical results, with preliminary results suggesting it
may slow disease progression [143]. If successful, this approach underscores the potential for myeloid
cell-based therapies for ALS.
4.3. Autoimmune Diseases: Multiple Sclerosis
Multiple sclerosis (MS) is a heterogeneous, chronic demyelinating disease affecting the CNS,
with unknown aetiology [144]. MS pathogenesis is characterized by early infiltration of leukocytes
into the brain and spinal cord, leading to discrete lesions and loss of associated axons [47]. Although
T cells play a central role in the progression of MS and its classical animal model experimental
autoimmune encephalomyelitis (EAE), innate immune activity is critical for the progression and
resolution of demyelination [145]. This involves marked but temporary monocyte extravasation across
CNS gateways to the parenchyma [146], and secretion of cytotoxic factors such as inflammatory
cytokines and reactive oxygen/nitrogen species by infiltrating inflammatory monocyte-derived
macrophages during the initiation of demyelination (the effector phase) [147,148]. Factors important
for the remyelination process include microglia/macrophage phagocytosis of debris and stimulation
of oligodendrocyte progenitor cell differentiation, via clearance of axonal debris and release of
neurotrophic molecules such as Activin A [147,149,150]. Also of note is the role of antigen presentation
to primed T cells by CD11c+ (primarily dendritic) cells located at the meninges and perivascular
spaces during the effector phase of EAE [151,152]. Historically, the distinction between resident
and infiltrating myeloid cells has been complicated by overlapping phenotypic characteristics of
reactive microglia and infiltrating monocyte-derived macrophages, as well as confounding effects
associated with conditioning for transplantation of labelled blood-derived cells [153]. Recently, a study
employing targeted expression of CCR2/CX3CR1 fluorescent reporters has uncovered distinct patterns
of behaviour and associated gene expression of CCR2+ monocyte-derived macrophages and resident
CX3CR1+ microglia during the induction phase of EAE [154]. Blood-derived cells were found in direct
contact with nodes of Ranvier and adopted a distinctly pro-inflammatory gene expression profile,
whereas microglia underwent marked downregulation of metabolic genes, made direct contact with
macrophages but not with axons, and appeared to be taking up myelin debris left by the infiltrating cells.
This raises the possibility that microglia may be particularly suited towards neuroprotection during
the initiation of MS, and indicates their gene expression profile may uncover some targets that could
be modified in blood-derived cells for therapeutic purposes. At this stage the contributions of myeloid
subsets to the resolution of demyelination are less clear, although both resident and infiltrating cells
appear to play a role in oligodendrocyte differentiation, and evidence points towards ‘M2’ polarization
as beneficial [153]. The heterogeneous phenotypes of macrophages along the ‘M1-M2’ spectrum might
be one of the reasons for such contradictory results in animal models of MS [155]. This complexity
is reflected in a study of tissue from multiple sclerosis patients, in which a significant number of
myeloid cells within chronic lesions expressed markers typical of both M1 and M2 states, namely
CD40 and mannose receptor [156]. It could be argued that these descriptors of polarization states as
M1/M2, or pro/anti-inflammatory are insufficient to properly characterize the parenchymal myeloid
cells response to stimuli [157]. It is also possible that this heterogeneity reflects the developmental
specialization of specific myeloid subsets, which has not yet been fully characterized.
Currently, the α4 integrin antibody natalizumab is used for management of relapsing-remitting
and progressive multiple sclerosis, with its therapeutic mode of action purported to involve its
inhibitory effect on T cell adhesion to vascular endothelium and subsequent extravasation into the
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brain parenchyma [158,159]. Monocytes also employ α4 integrins to cross the blood–brain barrier [160],
indicating they would be affected in a similar manner to therapy. Unfortunately, natalizumab
therapy carries a risk of potentially fatal progressive multifocal leukoencephalopathy caused by
the reactivation of latent John Cunningham (JC) virus, making it unsuitable for patients with latent
infection [161]. Interferon beta, an important immunomodulatory cytokine, has also been used to
prevent or reduce the number of MS relapses [162]. Although its many mechanisms of action are not
fully understood [163], in a rat model of EAE, interferon beta treatment was associated with a marked
reduction of monocyte infiltration to the perivascular space and concurrent downregulation of adhesion
molecule expression [164]. Studies have also shown that interferon beta can downregulate antigen
presentation in cultured peripheral and CNS-resident APCs via reductions in MCHII expression and
alterations in cytokine signalling [165], indicating its therapeutic activity may occur in the meninges,
choroid plexus and perivascular spaces, which are crucial locations for antigen presentation to T
lymphocytes in EAE [166]. Additionally, interferon beta appears to upregulate microglial clearance
of myelin and axonal debris [167,168]. Although moderately successful, therapy with interferons
is associated with numerous side effects, including a significantly increased risk of depression and
suicidal behaviour [162,169]. This is likely due to the broad range of effects of supraphysiological
systemic doses of an endogenous cytokine.
A number of clinical trials are currently underway utilizing the existing capabilities of immune
cells to modulate immune response in MS. Firstly, a trial of autologous hematopoietic stem cell
transplantation after non-myeloablative chemotherapy was recently conducted [170], with the aim to
eliminate autoreactive T cells and re-establish self-tolerance. Early reports indicate improvements in
symptoms and reduced frequency of relapses; however, this will need to be followed longer term to
determine whether the effect persists well beyond the usual course of disease. Particularly of interest
is whether ‘resetting’ the patient’s immune systems in this way is sufficient to halt reactivation of
T lymphocytes, or whether the transplanted cells may require enhancement to resist influence from
dysfunctional signalling outside of the hematopoietic compartment. A more targeted therapeutic
approach currently under investigation involves the use of tolerogenic dendritic cells (tolDCs) for the
suppression of cytotoxic T cell responses [171]. Although dendritic cells have long been recognized as
potent antigen-presenting cells, it has only recently been discovered that they can also regulate
autoreactive T cells via the induction of apoptosis, or by modulating their phenotype towards
a T-regulatory (Treg) cell profile [172]. Despite challenges with inducing a stable tolerogenic phenotype
in vitro, one laboratory has developed a method of inducing human and mouse tolDCs [173,174],
and has successfully applied MOG-loaded tolDCs to a mouse model of EAE with promising
results [174,175]. Further research, in particular the upcoming phase I clinical trial (NCT02618902), is
anticipated with interest.
4.4. Brain Tumours: Glioma
Malignant gliomas are aggressive tumours arising from cells of astrocyte, oligodendrocyte or
ependymal origin, comprising the most common form of malignant tumours on the CNS [176].
Prognosis is poor and recurrence is common, with chemotherapy, radiation, and surgical resection only
modestly extending average survival times [177,178]. Gliomas evade detection by inducing robust local
and systemic immunosuppression, and secreting immunosuppressive chemokines, prostaglandins,
and other ligands to protect themselves against adaptive and innate immune responses [179].
This is associated with increases in circulating T regulatory cells (Tregs) [180] and myeloid-derived
suppressor cells (MDSCs) [181], which are recruited to tumours by chemokines such as CCL2
released by tumour-associated microglia and macrophages [182]. Tumour-associated myeloid cells
contribute significantly to the tumour mass, and have been proposed to promote tumour growth,
survival, and invasion of surrounding tissues by producing growth factors, cytokines, and proteolytic
enzymes [179,183]. Alkylating agents such as temozolomide (TMZ) are the standard therapy for
glioblastoma, and commonly result in profound myelosuppression [184].
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Although myeloid cells undergo a distinct phenotypic shift on contact with the tumour
microenvironment, evidence suggests their activity may be required for protection against tumour
progression. A number of studies have demonstrated beneficial effects of macrophage/microglial
activation strategies such as Stat3 inhibitors [185] and Amphotericin B on protective responses to
glioma. Another study demonstrated that ganciclovir-mediated reduction in CD11b+ macrophages
led to increases in tumour volume in a syngeneic model of glioma, associated with reductions in
TNF-expressing cells and lymphocytes [186]. It could be speculated that incomplete removal of
myeloid cells in this study has spared particular subsets with especially detrimental effects on glioma
in isolation. In support of this, two recent studies have investigated the role of brain resident CD11b+
cells in the contribution to glioma progression, and have shown that resident rather than infiltrating
myeloid cells are the primary contributors to tumour growth and angiogenesis. In these studies,
head-shielded irradiation with or without selective ablation of CD11b+ microglia via intraventricular
ganciclovir infusion enabled the examination of relative contribution of resident and infiltrating
myeloid cells in GFP+ bone marrow chimeras [187,188]. Brain-resident cells comprised the majority of
tumour-associated macrophages, and their selective reduction slowed tumour growth and decreased
blood vessel density. This suggests microglia may be particularly responsible for the progression of
glioma, and raises the possibility that infiltrating myeloid cells are in fact protective. To confirm this
hypothesis, further phenotypic characterization will be required to identify cells as microglia. Once the
phenotypic and functional diversity of glioma-associated myeloid cells has been clarified, it may be
possible to target specific subsets directly to enhance protective functions or mitigate dysfunctional
interactions with the tumour microenvironment.
One strategy for overcoming robust immunosuppression in the glioma microenvironment is
enhancing the presentation of tumour-associated antigen to T cells prior to encountering the tumour.
In humans, this strategy has mostly revolved around dendritic cell-based vaccines, which were
initiated for other cancers in the 1990s and have undergone various modifications to improve
immunogenicity [189]. Currently there are dozens of phase I–II clinical trials employing vaccination
with autologous dendritic cells loaded with whole tumour lysate, and purified or synthetic antigen
peptides [190–193], with some indications of success associated with decreases in number of Treg cells
following treatment [194]. However, as of yet none have been particularly successful at addressing
the poor antigen-specific T cell response rates observed so far. This is possibly due to systemic
immunosuppression caused by the glioblastoma itself [195]. In the future it may become possible
to enhance dendritic cell function by altering genes involved in antigen presentation or response to
systemic immunosuppression, or it may be necessary to target a different subset of cells for optimal
response, such as tumour-associated macrophages/microglia [196]. Interestingly, transplantation of
gene-modified hematopoietic stem cells (the precursors to infiltrating macrophages) has also been
tested in humans, but only for the purpose of mediating the myeloablative side-effects of high dose
chemotherapy [197,198]. Nonetheless, these studies demonstrate that HSC transplantation is feasible,
which indicates that gene therapy involving HSCs may be a promising avenue for further investigation.
5. From Bench to Bedside: Targets for Future Research
Since the role of immune surveillance in the brain was first recognised, much has been learned
about the role of myeloid cells in the initiation and resolution of CNS disorders. In particular, the
past several years have seen the development of new, reliable methods of genetic modification that
have greatly accelerated our understanding of the CNS during health and disease. Despite this,
current strategies for harnessing the potential of the myeloid cell are yet to mature into reliable,
efficacious treatments.
We suspect this is because we are only just beginning to understand the true heterogeneity of the
hematopoietic system, particularly relating to cells found in the neurovascular unit. Despite recent
insights regarding the ontogeny and phenotype of these cells, many researchers continue to refer
to all phagocytic cells in the CNS as “microglia”. Therefore readers are strongly encouraged to
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evaluate the literature regarding neuro-inflammation and microglial activation with care, and to refrain
from equating microglia and CNS macrophages in their own research. This can now be achieved
relatively easily, as many reporter systems are available [10], and the transcriptional profiles of the
two major subsets are well characterized [22–24,34]. Additionally, novel methods of depleting specific
subsets of cells are under development [199], which may assist with the functional characterization
of the heterogeneous subsets of microglia and other myeloid cells without confounding effects of
irradiation on brain tissue, for example [200]. Additionally, a closer examination of the heterogeneous
states between the two poles of M1 and M2 activation in macrophages is needed to understand
which factors are most desirable for neuroprotection. M2 activation is generally considered the
desirable, neurotrophic phenotype, and M1 macrophages are thought to encourage neurodegeneration.
However, growing evidence suggests that both phenotypes, or perhaps an intermediary state, are
required for different phases of the neuro-immune response [201]. In addition, this schema may
be particularly inappropriate for characterizing responses of resident microglia to pathological
insults [157]. Undoubtedly, progress in fate mapping and identification of the various subsets of
myeloid cells will enable us to explore this issue further.
As cell-based therapies enter the clinic, new strategies for monitoring transplanted cells in vivo
will be required. The capacity to monitor the spatial distribution of myeloid cell homing will enable
clinicians to monitor the co-localization of transplanted cells with existing biomarkers of pathology,
which may enable them to examine outcomes earlier than is currently possible. The development of
new imaging modalities and reporter systems has progressed far in animal trials; however, challenges
associated with retention of labels, sensitivity, long-term safety, and viability of reporters have limited
its use in the clinic to date [202]. Until this has been optimized, clinicians may benefit from the
use of existing biomarkers of neuro-immune activity such as translocator protein (18 kDa, TSPO)
expression for the localization of activated microglia and infiltrating myeloid cells during disease and
therapy [203]. Positron emission tomography using TSPO ligands as markers of microglial activation
have been investigated for use in neurodegenerative diseases and multiple sclerosis [204,205], and are
under investigation for prediction and monitoring of disease progression [203,206]. Molecular imaging
with TSPO ligands has also been applied for non-invasive monitoring of glioma in a null-background
mouse model [207], and is under consideration for monitoring of key events in glioma progression
in humans [208]. Future work should focus on novel applications for existing non-invasive imaging
techniques, or identify additional strategies for non-invasive monitoring of cell trafficking and
associated neuro-immune activity.
Moving forward, myeloid-based cellular therapy appears to be heading in three general directions:
the enhancement of de novo immunomodulatory functions via in vitro stimulation with drugs,
peptides or antigens; the insertion or removal of genetic information to enhance neuroprotection
or eliminate neurodegenerative responses; or use as a “Trojan horse” for microvesicles containing
therapeutic molecules, enzymes or gene vectors intended for neurons [209,210] (Figure 3). In the gene
modification arena, optimized methods including lentiviral/adenoviral vectors and, most recently,
customizable nucleases such as zinc finger nucleases [211] and CRIPSR-cas9 [212] have recently been
developed, although it remains to be seen whether the efficiency, stability, and long-term safety of
these systems are sufficient for widespread use [213]. Likewise, microvesicle and nanoparticle-loaded
cell delivery is beginning to receive attention as a viable method of CNS therapeutic delivery, with
initial trials indicating it is possible to target the CNS with loaded macrophages [214]. Further study
will likely be needed to establish the optimal components and safe clearance of these delivery vehicles.
In summary, much progress has been made in the understanding of myeloid cell function.
However, much more remains to be learned regarding the functional and associated molecular
heterogeneity of myeloid subsets and their transport in and out of the brain. Current advances
in neuro-immunology, genetics, and biotechnology hold great potential for the treatment of some of
the most persistent and devastating illnesses affecting the CNS. We anticipate many new insights will
be gained as a result of these efforts.
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taking up drug-loaded nanoparticles intended for delivery into the CNS. Gene editing enables the 
up/downregulation of existing functions to enhance protective, or eliminate damaging responses to 
disease. It is also possible to introduce expression of enzymes not usually present in these cells 
through this process. Another strategy for guiding myeloid cell-based therapies in the CNS involves 
in vitro manipulation of polarisation or differentiation, for example with cytokines or drugs known 
to guide the cells into a more neuroprotective phenotype. As a result of in vitro manipulation, myeloid 
cells returned to the circulation may then be better capable of ameliorating brain pathology by one of 
several mechanisms. For example, CNS-infiltrating myeloid cells may be better equipped to release 
compounds with growth or survival-promoting effects on nearby diseased neurons. Alternatively, it 
may be possible to enhance the capacity of infiltrating cells to present brain-derived antigens to the 
adaptive immune system, thus enhancing clearance of unwanted protein products. Myeloid cells may 
also be used to enhance the clearance of excess waste or diseased tissue independently via 
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Figure 3. Strategies for enhancing myeloid cell therapy for the CNS. The phagocytic capacity of
myeloid cells may be adapted for use as delivery vehicles for compounds, antigens, or microvesicles
loaded with therapeutic substances destined for the brain. Pictured is a macrophage in the process
of taking up drug-loaded nanoparticles intended for delivery into the CNS. Gene editing enables the
up/downregulation of existing functions to enhance protective, or eliminate damaging responses
to disease. It is also possible to introduce expression of enzymes not usually present in these cells
through this process. Another strategy for guiding myeloid cell-based therapies in the CNS involves
in vitro manipulation of polarisation or differentiation, for example with cytokines or drugs known to
guide the cells into a more neuroprotective phenotype. As a result of in vitro manipulation, myeloid
cells returned to the circulation may then be better capable of ameliorating brain pathology by one of
several mechanisms. For example, CNS-infiltrating myeloid cells may be better equipped to release
compounds with growth or survival-promoting effects on nearby diseased neurons. Alternatively,
it may be possible to enhance the capacity of infiltrating cells to present brain-derived antigens to the
adaptive immune system, thus enhancing clearance of unwanted protein products. Myeloid cells may
also be used to enhance the clearance of excess waste or diseased tissue independently via phagocytosis.
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